ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes

Type 1 Diabetes Clinical Trial

— ADAPT  

Official title:

ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04235504
• Other study ID #: CIP327
• Status: Completed
• Phase: N/A
• Start date: July 13, 2020
• Est. completion date: May 30, 2022

Study information

• Verified date: March 2023
• Source: Medtronic Diabetes
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study evaluate the safety and efficacy of the Advanced Hybrid Closed Loop (AHCL) system in sub-optimally controlled patients with T1D, in comparison with Multiple Daily Injection (MDI) therapy with Flash Glucose Monitoring (FGM) or Continuous Glucose Monitoring (CGM). Patient with a diagnosis of Type 1 diabetes currently under MDI+ FGM or MDI+ CGM therapy will be enrolled.

Description:

This study is a pre-market, multi-center, prospective, open label, adaptative, randomized controlled trial in insulin-requiring adult subjects with type 1 diabetes on MDI therapy. The study will have three period: 1. Run-in Phase: The Run-in period is of 4 weeks (and can be extended for 2 additional ones) during which time a blinded CGM sensor will be worn for two weeks. 2. Study Phase: There will be a 6 months randomized study period with two arms: Treatment Arm (AHCL) and the Control Arm. 3. Continuation Phase: There will be a 6 months continuation phase during which time all the subjects will use the AHCL system. Approximately 124 subjects will be enrolled in the study up to 20 investigational centers in EMEA.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 122
• Est. completion date: May 30, 2022
• Est. primary completion date: December 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject is age = 18 years old at time of screening

2. Subject has a clinical diagnosis of Type 1 diabetes for = 2 years prior to screening as determined via source documentation

3. On MDI therapy (defined as = 3 insulin injections per day and/or a basal/bolus regimen) = 2 years prior to screening

4. Subject has been followed and treated by the investigator at this investigational site for at least 3 months prior to screening and subject has already undergone local educational therapeutic programs.

5. Subject is using:

• Flash Glucose Monitoring (FGM) for = 3 months with a daily average number of scans = 5 over and with sensor readings > 70% of time over the previous month prior to screening (based on sensor usage from the download summary report of the FGM system over 30 days prior to screening) Or
• Continuous Glucose Monitoring (CGM) for = 3 months with a frequency of sensor use = 70% of the time over the previous month prior to screening (based on download summary report from the CGM system over 30 days prior to screening).

6. Subject has a glycosylated hemoglobin (HbA1c) = 8.0% (64 mmol/mol) at time of screening visit (as processed by a Central Lab).

7. Subject is willing to take or switch to one of the following insulins:

1. Humalog™ (insulin lispro injection)

2. NovoLog™ (insulin aspart)

8. Subject must have a minimum daily insulin requirement (Total Daily Dose) of = 8 units and a maximum of 250 units.

9. Subject is willing to upload data from the study pump and meter, must have Internet access and a compatible computer system that meets the requirements for uploading the study pump data at home.

10. Subject is willing and able to sign and date informed consent, comply with all study procedures and wear all study devices, as required during the study.

Exclusion Criteria:

1. Subject has untreated Addison's disease, thyroid disorder, growth hormone deficiency, hypopituitarism or definite gastroparesis, per investigator judgment.

2. Subject is using pramlintide, DPP-4 inhibitor, GLP-1 agonists/mimetics, metformin, SGLT2 inhibitors at time of screening.

3. Subject has had renal failure defined by creatinine clearance <30 ml/min, as assessed by local lab test = 12 months before screening or performed at screening at local lab, as defined by the creatinine-based Cockcroft or MDRD equations.

4. Subject is planning to switch from FGM to CGM therapy during the 6 months study phase. Note: Subject randomized to Control Arm should remain on their current FGM or CGM therapy during the study phase and will be switched to AHCL during the continuation phase.

5. Subject has a history of hearing or vision impairment hindering perception of glucose display and alarms, or otherwise incapable of using the study devices, per investigator judgment.

6. Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study.

7. Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study, per investigator judgment.

8. Subject has any unresolved adverse skin conditions in the area of sensor placement (e.g. psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).

9. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or device in the last 2 weeks before enrollment into this study, as per investigator judgment.

10. Subject is currently abusing illicit drugs, marijuana, alcohol or prescription drugs (other than nicotine), per investigator judgment.

11. Subject has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.

12. Subject is legally incompetent, illiterate or vulnerable person.

13. Research staff involved with the study.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Other:
• MDI
Subject continues their standard Multiple Daily Injections therapy with FGM or RT-CGM

Device:
• AHCL
Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0. Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment.

Locations

Country	Name	City	State
France	Centre Hospitalier Universitaire Besancon - Hôpital Jean Minjoz	Besançon
France	CHU de Bordeaux - Hôpital Saint André	Bordeaux
France	CHU Caen	Caen
France	Hospices Civils de Lyon (DIAB-e CARE)	Lyon
France	APM - Hôpital de la Conception	Marseille
France	Hospital Civil	Strasbourg
Germany	Diabetologische Schwerpunktpraxis Dr. Ralf Kolassa	Bergheim
Germany	Zentrum für Diabetologie Bergedorf	Hamburg
Germany	Gemeinschaftspraxis im Westtor Hausarztpraxis & Diabetologische Schwerpunktpraxis	Lage
Germany	Medical Center am Clemenshospital Dr. Winfried Keuthage	Münster
United Kingdom	Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital	Cambridge
United Kingdom	Harrogate and District Hospital - NHS Foundation Trust	Harrogate
United Kingdom	University Hospitals of Leicester NHS Trust Leicester General Hospital	Leicester
United Kingdom	King's College Hospital NHS Foundation Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Diabetes

Countries where clinical trial is conducted

France,  Germany,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	HbA1c 6 Months Change Between AHCL and MDI	The difference in the mean HbA1c change (6 months - baseline) between the AHCL and the MDI + CGM arm will be evaluated (Cohort B).	Baseline and end of 6-month study phase
Other	TIR Between 70-180 mg/dL	% Time spent within range with sensor glucose (SG) between 70 - 180 mg/dL (3.9-10.0 mmol/L). The difference in the mean between the AHCL and the MDI + CGM arm will be evaluated (Cohort B).	6 months study phase
Other	Time in Hyperglycemic Range	% Time spent in hyperglycemic range with SG > 180 mg/dL (> 10.0 mmol/L). The difference in the mean between the AHCL and the MDI + CGM arm will be evaluated (Cohort B).	6 months study phase
Other	Hypoglycemic Events	Number of biochemical hypoglycemic events< 54 mg/dL (3.0 mmol/L) (defined as sensor values < 54 mg/dL (3.0 mmol/L) per 15 consecutive minutes (Danne, 2017). When the time between two successive events is less than 30 minutes, they will be combined and counted as one event. The difference in the mean between the AHCL and the MDI + CGM arm will be evaluated (Cohort B).	6 months study phase
Other	HbA1c 6 Months Change Within Group	The change in the mean HbA1c from end of 6-month study phase to end of 6-month continuation phase will be evaluated (Cohort A)	End of 6-month study phase and end of 6-month continuation phase
Other	HbA1c 12 Months Change Between Groups	The difference in the mean HbA1c change (12 months - baseline) between treatment arm and control arm will be evaluated (Cohort A)	Baseline through the end of 6-month continuation phase (a total of 12 months)
Other	HbA1c 6 Months Change Within Group	The change in the mean HbA1c from end of 6-month study phase to end of 6-month continuation phase will be evaluated (Cohort B).	End of 6-month study phase and end of 6-month continuation phase
Other	HbA1c 12 Months Change Between Groups	The difference in the mean HbA1c change (12 months - baseline) between treatment arm and control arm will be evaluated (Cohort B).	Baseline through the end of 6-month continuation phase (a total of 12 months).
Primary	HbA1c 6 Months Change Between AHCL and MDI	The difference in the mean HbA1c change (6 months - baseline) between the AHCL and the MDI + FGM arm will be evaluated (Cohort A).	Baseline and end of 6-month study phase
Secondary	TIR Between 70-180 mg/dL	% Time spent within range with sensor glucose (SG) between 70 - 180 mg/dL (3.9-10.0 mmol/L). The difference in the mean between the AHCL and the MDI + FGM arm will be evaluated (Cohort A).	6 months study phase
Secondary	Time in Hyperglycemic Range	% Time spent in hyperglycemic range with SG > 180 mg/dL (> 10.0 mmol/L). The difference in the mean between the AHCL and the MDI + FGM arm will be evaluated (Cohort A).	6 months study phase
Secondary	Hypoglycemic Events	Number of biochemical hypoglycemic events< 54 mg/dL (3.0 mmol/L) (defined as sensor values < 54 mg/dL (3.0 mmol/L) per 15 consecutive minutes (Danne, 2017). When the time between two successive events is less than 30 minutes, they will be combined and counted as one event. The difference in the mean between the AHCL and the MDI + FGM arm will be evaluated (Cohort A)	6 months study phase